What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myelofibrosis treatment has advanced with janus kinase (JAK) inhibitors like ruxolitinib.
• JAK inhibitors offer targeted therapy but do not eradicate the disease.
• Novel therapeutic strategies are needed for myelofibrosis.

Purpose of the Study:

• To review novel agents with mechanisms of action complementary to JAK2 inhibition for myelofibrosis.
• To discuss emerging therapies in preclinical and clinical development for myelofibrosis.

Main Methods:

• Review of preclinical and clinical data on novel myelofibrosis agents.
• Analysis of compounds targeting heat shock proteins, histone deacetylase, transforming growth factor-β, and lysyl oxidase like-2.
• Evaluation of agents inhibiting signal transducer and activator of transcription 5 (STAT5).

Main Results:

• Heat shock protein inhibitors and histone deacetylase inhibitors promote JAK2 degradation and overcome resistance.
• Monoclonal antibodies targeting TGF-β and LOXL2 show potential for reversing bone marrow fibrosis.
• Compounds inhibiting STAT5 activity and promoting megakaryocyte polyploidization are under investigation.

Conclusions:

• Several novel agents are in clinical trials for myelofibrosis, alone or in combination with JAK inhibitors.
• These new drugs are not yet approved but show promising activity.
• Patients with myelofibrosis, especially those refractory to JAK inhibitors, should consider clinical trial participation.